Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

Eli Lilly (NYSE:LLY) has recently announced several developments, including positive Phase 2 results for their siRNA therapy ...

Lepodisiran targets “elevated lipoprotein(a)” — also known as Lp(a) — which is a genetically inherited cardiovascular risk factor that affects about 20% of Americans. And about a quarter ...

Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein(a) levels by more than 90% for at least six months with a single injection in a phase 2 trial, reinforcing its ...

But, he continued, “these significant and sustained Lp(a) reductions are encouraging and suggest that siRNA approaches like lepodisiran could potentially offer durable benefits with long-term ...

On Sunday, researchers announced that an experimental drug from Eli Lilly, lepodisiran, reduced levels of Lp (a) by a ...

However, the US drug maker Eli Lilly's new experimental drug, lepodisiran, has shown promising results in reducing levels of lipoprotein(a), the main genetically inherited risk factor for the ...